-
1
-
-
84927150740
-
Immune checkpoint blockade in cancer therapy
-
Postow, MA, Callahan, MK, Wolchok, JD, Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1974-1982
-
-
Postow, M.A.1
Callahan, M.K.2
Wolchok, J.D.3
-
2
-
-
85045378539
-
Cancer immunotherapy using checkpoint blockade
-
Ribas, A, Wolchok, JD, Cancer immunotherapy using checkpoint blockade. Science 359 (2018), 1350–1355.
-
(2018)
Science
, vol.359
, pp. 1350-1355
-
-
Ribas, A.1
Wolchok, J.D.2
-
3
-
-
84994144982
-
Fulminant myocarditis with combination immune checkpoint blockade
-
Johnson, DB, Balko, JM, Compton, ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
-
(2016)
N Engl J Med
, vol.375
, pp. 1749-1755
-
-
Johnson, D.B.1
Balko, J.M.2
Compton, M.L.3
-
4
-
-
85042943560
-
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
-
Moslehi, JJ, Salem, JE, Sosman, JA, Lebrun-Vignes, B, Johnson, DB, Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, 391, 2018, 933.
-
(2018)
Lancet
, vol.391
, pp. 933
-
-
Moslehi, J.J.1
Salem, J.E.2
Sosman, J.A.3
Lebrun-Vignes, B.4
Johnson, D.B.5
-
5
-
-
85042935565
-
Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity
-
Escudier, M, Cautela, J, Malissen, N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136 (2017), 2085–2087.
-
(2017)
Circulation
, vol.136
, pp. 2085-2087
-
-
Escudier, M.1
Cautela, J.2
Malissen, N.3
-
6
-
-
85043452821
-
Myocarditis in patients treated with immune checkpoint inhibitors
-
Mahmood, SS, Fradley, MG, Cohen, JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 (2018), 1755–1764.
-
(2018)
J Am Coll Cardiol
, vol.71
, pp. 1755-1764
-
-
Mahmood, S.S.1
Fradley, M.G.2
Cohen, J.V.3
-
7
-
-
53849138066
-
VigiBase, the WHO global ICSR database system: basic facts
-
Lindquist, M, VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 42 (2008), 409–419.
-
(2008)
Drug Inf J
, vol.42
, pp. 409-419
-
-
Lindquist, M.1
-
8
-
-
0031871338
-
A Bayesian neural network method for adverse drug reaction signal generation
-
Bate, A, Lindquist, M, Edwards, IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54 (1998), 315–321.
-
(1998)
Eur J Clin Pharmacol
, vol.54
, pp. 315-321
-
-
Bate, A.1
Lindquist, M.2
Edwards, I.R.3
-
9
-
-
84862216660
-
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
-
Noren, GN, Hopstadius, J, Bate, A, Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22 (2013), 57–69.
-
(2013)
Stat Methods Med Res
, vol.22
, pp. 57-69
-
-
Noren, G.N.1
Hopstadius, J.2
Bate, A.3
-
10
-
-
16244414305
-
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death
-
De Bruin, ML, Pettersson, M, Meyboom, RH, Hoes, AW, Leufkens, HG, Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26 (2005), 590–597.
-
(2005)
Eur Heart J
, vol.26
, pp. 590-597
-
-
De Bruin, M.L.1
Pettersson, M.2
Meyboom, R.H.3
Hoes, A.W.4
Leufkens, H.G.5
-
11
-
-
4544368008
-
The reporting odds ratio and its advantages over the proportional reporting ratio
-
Rothman, KJ, Lanes, S, Sacks, ST, The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13 (2004), 519–523.
-
(2004)
Pharmacoepidemiol Drug Saf
, vol.13
, pp. 519-523
-
-
Rothman, K.J.1
Lanes, S.2
Sacks, S.T.3
-
12
-
-
85049141577
-
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors
-
Grouthier, V, Lebrun-Vignes, B, Glazer, AM, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart 104 (2018), 1859–1863.
-
(2018)
Heart
, vol.104
, pp. 1859-1863
-
-
Grouthier, V.1
Lebrun-Vignes, B.2
Glazer, A.M.3
-
13
-
-
85040654063
-
Immune-related adverse events associated with immune checkpoint blockade
-
Postow, MA, Sidlow, R, Hellmann, MD, Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378 (2018), 158–168.
-
(2018)
N Engl J Med
, vol.378
, pp. 158-168
-
-
Postow, M.A.1
Sidlow, R.2
Hellmann, M.D.3
-
14
-
-
85047796335
-
Immune checkpoint inhibitors and cardiac toxicity: an emerging issue
-
Varricchi, G, Marone, G, Mercurio, V, Galdiero, MR, Bonaduce, D, Tocchetti, CG, Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem 25 (2018), 1327–1339.
-
(2018)
Curr Med Chem
, vol.25
, pp. 1327-1339
-
-
Varricchi, G.1
Marone, G.2
Mercurio, V.3
Galdiero, M.R.4
Bonaduce, D.5
Tocchetti, C.G.6
-
15
-
-
85047095751
-
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
-
Conforti, F, Pala, L, Bagnardi, V, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol 19 (2018), 737–746.
-
(2018)
Lancet Oncol
, vol.19
, pp. 737-746
-
-
Conforti, F.1
Pala, L.2
Bagnardi, V.3
-
16
-
-
85043306908
-
Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
-
Wu, Y, Ju, Q, Jia, K, et al. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Int J Cancer 143 (2018), 45–51.
-
(2018)
Int J Cancer
, vol.143
, pp. 45-51
-
-
Wu, Y.1
Ju, Q.2
Jia, K.3
-
17
-
-
0035846991
-
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
-
Nishimura, H, Okazaki, T, Tanaka, Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 (2001), 319–322.
-
(2001)
Science
, vol.291
, pp. 319-322
-
-
Nishimura, H.1
Okazaki, T.2
Tanaka, Y.3
-
18
-
-
85042198550
-
Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology
-
Varricchi, G, Galdiero, MR, Tocchetti, CG, Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation 136 (2017), 1989–1992.
-
(2017)
Circulation
, vol.136
, pp. 1989-1992
-
-
Varricchi, G.1
Galdiero, M.R.2
Tocchetti, C.G.3
-
19
-
-
85033784005
-
Survival after fulminant myocarditis induced by immune-checkpoint inhibitors
-
Arangalage, D, Delyon, J, Lermuzeaux, M, et al. Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167 (2017), 683–684.
-
(2017)
Ann Intern Med
, vol.167
, pp. 683-684
-
-
Arangalage, D.1
Delyon, J.2
Lermuzeaux, M.3
-
20
-
-
85039050365
-
Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab
-
Nasr, F, El Rassy, E, Maalouf, G, et al. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 91 (2018), 171–173.
-
(2018)
Eur J Cancer
, vol.91
, pp. 171-173
-
-
Nasr, F.1
El Rassy, E.2
Maalouf, G.3
-
21
-
-
85039950523
-
Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists
-
Frigeri, M, Meyer, P, Banfi, C, et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol 34 (2018), 92.e1–92.e3.
-
(2018)
Can J Cardiol
, vol.34
, pp. 92.e1-92.e3
-
-
Frigeri, M.1
Meyer, P.2
Banfi, C.3
-
22
-
-
84950117835
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
-
Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
-
(2016)
Lancet
, vol.387
, pp. 1540-1550
-
-
Herbst, R.S.1
Baas, P.2
Kim, D.W.3
-
23
-
-
84953874197
-
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
-
Sharabi, AB, Lim, M, DeWeese, TL, Drake, CG, Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16 (2015), e498–e509.
-
(2015)
Lancet Oncol
, vol.16
, pp. e498-e509
-
-
Sharabi, A.B.1
Lim, M.2
DeWeese, T.L.3
Drake, C.G.4
-
24
-
-
21144454783
-
Relation of acute pericardial disease to malignancy
-
Imazio, M, Demichelis, B, Parrini, I, et al. Relation of acute pericardial disease to malignancy. Am J Cardiol 95 (2005), 1393–1394.
-
(2005)
Am J Cardiol
, vol.95
, pp. 1393-1394
-
-
Imazio, M.1
Demichelis, B.2
Parrini, I.3
-
25
-
-
85045839872
-
Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
-
Tocut, M, Brenner, R, Zandman-Goddard, G, Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17 (2018), 610–616.
-
(2018)
Autoimmun Rev
, vol.17
, pp. 610-616
-
-
Tocut, M.1
Brenner, R.2
Zandman-Goddard, G.3
-
26
-
-
85042364101
-
Checks and balances in autoimmune vasculitis
-
Hid Cadena, R, Abdulahad, WH, Hospers, GAP, et al. Checks and balances in autoimmune vasculitis. Front Immunol, 9, 2018, 315.
-
(2018)
Front Immunol
, vol.9
, pp. 315
-
-
Hid Cadena, R.1
Abdulahad, W.H.2
Hospers, G.A.P.3
-
27
-
-
75649122868
-
CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis
-
Kamesh, L, Heward, JM, Williams, JM, et al. CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. Rheumatology 48 (2009), 1502–1505.
-
(2009)
Rheumatology
, vol.48
, pp. 1502-1505
-
-
Kamesh, L.1
Heward, J.M.2
Williams, J.M.3
-
28
-
-
85014388193
-
A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis
-
Langford, CA, Cuthbertson, D, Ytterberg, SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69 (2017), 837–845.
-
(2017)
Arthritis Rheumatol
, vol.69
, pp. 837-845
-
-
Langford, C.A.1
Cuthbertson, D.2
Ytterberg, S.R.3
-
29
-
-
85019544751
-
Immune checkpoint dysfunction in large and medium vessel vasculitis
-
Watanabe, R, Zhang, H, Berry, G, Goronzy, JJ, Weyand, CM, Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 312 (2017), H1052–H1059.
-
(2017)
Am J Physiol Heart Circ Physiol
, vol.312
, pp. H1052-H1059
-
-
Watanabe, R.1
Zhang, H.2
Berry, G.3
Goronzy, J.J.4
Weyand, C.M.5
-
30
-
-
17244363866
-
Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis
-
Salvarani, C, Cimino, L, Macchioni, P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53 (2005), 293–297.
-
(2005)
Arthritis Rheum
, vol.53
, pp. 293-297
-
-
Salvarani, C.1
Cimino, L.2
Macchioni, P.3
-
31
-
-
85053689477
-
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis
-
published online Sept 13.
-
Wang, DY, Salem, JE, Cohen, JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 2018 published online Sept 13. DOI:10.1001/jamaoncol.2018.3923.
-
(2018)
JAMA Oncol
-
-
Wang, D.Y.1
Salem, J.E.2
Cohen, J.V.3
|